RT @lamelaspablo: @kaulcsmc @DrMoritzWvB @DrChuckSimonton @rwyeh @JWMoses @ron_waksman @djc795 @mirvatalasnag @prkothapalli @SachinGoelMD @…

@kaulcsmc @DrMoritzWvB @DrChuckSimonton @rwyeh @JWMoses @ron_waksman @djc795 @mirvatalasnag @prkothapalli @SachinGoelMD @NimeshDesaiMD @tomcnguyen @fischman_david @pomyers @gbiondizoccai @GAilawadiMD @mmamas1973 @mandeep_mayo @drjohnm @BavariaMd @dr_benoy_

RT @lamelaspablo: @djc795 @kaulcsmc @SripalBangalore @DFCapodanno @arnoldgehrke Composite outcomes of PCI vs CABG should not include repeat…

@djc795 @kaulcsmc @SripalBangalore @DFCapodanno @arnoldgehrke Composite outcomes of PCI vs CABG should not include repeat revasc, for multiple clinical and methodological issues expanded here @RichardWhitloc2 @GreggWStone https://t.co/tpuEwsPx3E too many t

RT @mmamas1973: @VictorDayan1 @BruckelJeffrey so if thresholds for revasc differ, then undoubtedly revasc rates will be different by differ…

RT @mmamas1973: @VictorDayan1 @BruckelJeffrey so if thresholds for revasc differ, then undoubtedly revasc rates will be different by differ…

@VictorDayan1 @BruckelJeffrey so if thresholds for revasc differ, then undoubtedly revasc rates will be different by different modalities. Also important to consider that revasc only has a prognostic benefit if early, when late less evident. This paper is

Lors du choix d'une stratégie de revascularisation (ACT ou PAC), médecins et patients n'ont pas les mêmes inquiétudes When discussing a revascularization strategy (PCI vs CABG), doctors and patients do not have the same views on adverse events ▶️https:/

@mmamas1973 @UjjwalRastogiMD @MohanedEgred @DrMauricioCohen @CESARJERONIMOVS @DrFerNunez @ferdikiem @omendiz @Izanagi_no_mi_ @IamSpurs @drsonyaburgess @DocCards @JosLudwig @NitiCardio @Drroxmehran @islamelgendy83 @Radial_ICG @EugeniaGianos Although I belie

RT @TKDsosyal: A hot topic in cardiology🚨🚨🚨. What is the impact and limitation of repeat revascularization as an outcome measure in the con…

RT @TKDsosyal: A hot topic in cardiology🚨🚨🚨. What is the impact and limitation of repeat revascularization as an outcome measure in the con…

RT @TKDsosyal: A hot topic in cardiology🚨🚨🚨. What is the impact and limitation of repeat revascularization as an outcome measure in the con…

RT @TKDsosyal: A hot topic in cardiology🚨🚨🚨. What is the impact and limitation of repeat revascularization as an outcome measure in the con…

RT @TKDsosyal: A hot topic in cardiology🚨🚨🚨. What is the impact and limitation of repeat revascularization as an outcome measure in the con…

RT @TKDsosyal: A hot topic in cardiology🚨🚨🚨. What is the impact and limitation of repeat revascularization as an outcome measure in the con…

A hot topic in cardiology🚨🚨🚨. What is the impact and limitation of repeat revascularization as an outcome measure in the context of PCI vs CABG clinical trials? https://t.co/GwdnREK71g @GreggWStone @lamelaspablo @JACCJournals https://t.co/LOKpGzBMzZ

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @jedicath: @XiangkeH @NielsRHolm https://t.co/uJGI8RBOpt

@XiangkeH @NielsRHolm https://t.co/uJGI8RBOpt

RT @JACCJournals: Should we be using more than repeat revascularization as an endpoint for trials comparing #PCI and #cvCABG? Dr. @GreggWS…

There is no way to compare pear with apple, “they are all fruits, but different fruits” #Cardiotwitter

RT @KPujdak: Well worth reading https://t.co/1wcwEBF4QB

Well worth reading

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @AJuradoRoman: I could not agree more. Repeat revasc should not be included in composite EP of trials comparing #PCI VS #CABG https://t.…

I could not agree more. Repeat revasc should not be included in composite EP of trials comparing #PCI VS #CABG

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @INC_CathLab: Repeat revasc analysis as an outcome of #PCI vs #CABG from @lamelaspablo and @cardiomicsclub! Are we properly using data…

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

This is an epic paper. Absolutely nails the essence of what we see on a day to day basis.

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

Repeat revasc as an endpoint is biased against PCI vs CABG for several reasons. Eg, long-term SVG < DES patency, yet DES restenosis more likely to be revascularized than SVG occlusion for technical and other reasons. Great thread by @lamelaspablo 👏

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @INC_CathLab: Repeat revasc analysis as an outcome of #PCI vs #CABG from @lamelaspablo and @cardiomicsclub! Are we properly using data…

RT @INC_CathLab: Repeat revasc analysis as an outcome of #PCI vs #CABG from @lamelaspablo and @cardiomicsclub! Are we properly using data…

Repeat revasc analysis as an outcome of #PCI vs #CABG from @lamelaspablo and @cardiomicsclub! Are we properly using data about “#TLF”? @drgianma @Dr_DanMD @dragustinr @mmamas1973 @jgloyo @HadyLichaaMD @billgogas @gdodo92 @Eri_Ont @gonzaeperez @hect2701

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @JACCJournals: Should we be using more than repeat revascularization as an endpoint for trials comparing #PCI and #cvCABG? Dr. @GreggWS…

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @Ortega_Paz: #EAPCI @PCRonline https://t.co/WvBWYAtc2f

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @Ortega_Paz: #EAPCI @PCRonline https://t.co/WvBWYAtc2f

#EAPCI @PCRonline

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @lamelaspablo: Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1)…

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

Readdressing the validity of repeat revascularization as an outcome measure in #PCI Vs #CABG. For readers in a hurry: 1) visit @cardiomicsclub https://t.co/MOd2nZUeML 2) go to @JACCJournals and listen podcast https://t.co/HyPMTWm7n4 3) read this thread!

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @JACCJournals: Should we be using more than repeat revascularization as an endpoint for trials comparing #PCI and #cvCABG? Dr. @GreggWS…

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

No podemos evaluar seriamente y extraer conclusiones definitivas de ninguna estrategia en base la necesidad de nueva revascularizacion! Es un endpoint muy variable y poco fiable

RT @JACCJournals: #JACC Review Topic of the Week: Repeat revascularization is a frequently assessed measure in trials comparing #PCI and #c…

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

RT @JACCJournals: Should we be using more than repeat revascularization as an endpoint for trials comparing #PCI and #cvCABG? Dr. @GreggWS…

RT @JACCJournals: Should we be using more than repeat revascularization as an endpoint for trials comparing #PCI and #cvCABG? Dr. @GreggWS…

Should we be using more than repeat revascularization as an endpoint for trials comparing #PCI and #cvCABG? Dr. @GreggWStone and colleagues explain the limitations behind this form of measurement in this week's issue. https://t.co/w0crzGP60C #JACC @Greg

RT @ICBAonline: Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artícul…

Felicitamos a los Dres Pablo Lamelas y Jorge Belardi por su artículo publicado en la prestigiosa revista JACC. Este artículo tiene el potencial de cambiar el rumbo de nuevas recomendaciones médicas y darle un enfoque distinto a estudios científicos futuros

👌 good algorithm

RT @JACCJournals: #JACC Review Topic of the Week: Repeat revascularization is a frequently assessed measure in trials comparing #PCI and #c…

RT @JACCJournals: #JACC Review Topic of the Week: Repeat revascularization is a frequently assessed measure in trials comparing #PCI and #c…

RT @JACCJournals: #JACC Review Topic of the Week: Repeat revascularization is a frequently assessed measure in trials comparing #PCI and #c…

RT @JACCJournals: #JACC Review Topic of the Week: Repeat revascularization is a frequently assessed measure in trials comparing #PCI and #c…

RT @JACCJournals: #JACC Review Topic of the Week: Repeat revascularization is a frequently assessed measure in trials comparing #PCI and #c…

RT @JACCJournals: #JACC Review Topic of the Week: Repeat revascularization is a frequently assessed measure in trials comparing #PCI and #c…

RT @JACCJournals: #JACC Review Topic of the Week: Repeat revascularization is a frequently assessed measure in trials comparing #PCI and #c…

@agtruesdell @naderjo https://t.co/HuaGhpzYAJ

RT @JACCJournals: #JACC Review Topic of the Week: Repeat revascularization is a frequently assessed measure in trials comparing #PCI and #c…

#JACC Review Topic of the Week: Repeat revascularization is a frequently assessed measure in trials comparing #PCI and #cvCABG, but are there issues with prioritizing this endpoint? Dr. @GreggWStone and colleagues provide their insights. https://t.co/w0crz

RT @lucreciamburgos: Felicitaciones por la revision @lamelaspablo y Jorge Belardi! "Limitations of Repeat Revascularization as an Outcome…

RT @PHRIresearch: .@lamelaspablo @RichardWhitloc2 @GreggWStone https://t.co/uS01E1SYGQ @JACCJournals

.@lamelaspablo @RichardWhitloc2 @GreggWStone https://t.co/uS01E1SYGQ @JACCJournals

RT @ValleAlfonso: Limitations of Repeat Revascularization as an Outcome Measure➡️ repeat revascularization should not be used ⛔️as a compon…

RT @lucreciamburgos: Felicitaciones por la revision @lamelaspablo y Jorge Belardi! "Limitations of Repeat Revascularization as an Outcome…

RT @ValleAlfonso: Limitations of Repeat Revascularization as an Outcome Measure➡️ repeat revascularization should not be used ⛔️as a compon…

RT @lucreciamburgos: Felicitaciones por la revision @lamelaspablo y Jorge Belardi! "Limitations of Repeat Revascularization as an Outcome…

RT @lucreciamburgos: Felicitaciones por la revision @lamelaspablo y Jorge Belardi! "Limitations of Repeat Revascularization as an Outcome…

RT @ValleAlfonso: Limitations of Repeat Revascularization as an Outcome Measure➡️ repeat revascularization should not be used ⛔️as a compon…

RT @ValleAlfonso: Limitations of Repeat Revascularization as an Outcome Measure➡️ repeat revascularization should not be used ⛔️as a compon…

RT @ferbotto: Great article ⁦@lamelaspablo⁩ !!Limitations of Repeat Revascularization as an Outcome Measure | JACC: Journal of the American…

RT @lucreciamburgos: Felicitaciones por la revision @lamelaspablo y Jorge Belardi! "Limitations of Repeat Revascularization as an Outcome…

RT @lucreciamburgos: Felicitaciones por la revision @lamelaspablo y Jorge Belardi! "Limitations of Repeat Revascularization as an Outcome…

RT @lucreciamburgos: Felicitaciones por la revision @lamelaspablo y Jorge Belardi! "Limitations of Repeat Revascularization as an Outcome…

RT @ValleAlfonso: Limitations of Repeat Revascularization as an Outcome Measure➡️ repeat revascularization should not be used ⛔️as a compon…

RT @lucreciamburgos: Felicitaciones por la revision @lamelaspablo y Jorge Belardi! "Limitations of Repeat Revascularization as an Outcome…